Gene test could revolutionize prostate cancer screening

NCT ID NCT07265414

Ongoing Diagnosis Sponsor: Istituto Clinico Humanitas Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether men with certain gene mutations (DRG) could benefit from a more tailored screening for prostate cancer. Researchers will test a combination of a blood test (PHI) and a special MRI scan in 320 men with or at risk for prostate cancer. The goal is to see if this approach finds cancers earlier and more accurately than the current PSA test and digital rectal exam.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Screening platform combining PHI blood test and mp-MRI scan
What this could lead to: If successful, this could lead to a more effective, personalized screening approach for men with DRG mutations, catching prostate cancer earlier and reducing both overdiagnosis and missed cases.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly improve outcomes. The approach may not prove better than standard screening, and results may not apply to all men.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER PROSTATE CANCER

Contacts and locations

Locations

IRCCS Humanitas Research Hospital

Milan, 20089, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.